Navigation Links
IsoPlexis Collaboration Offers Breakthrough Insights into Detecting and Predicting Patient Response to T-Cell Therapy
Date:4/3/2017

WASHINGTON, April 3, 2017 /PRNewswire-USNewswire/ -- Data captured by IsoCode, IsoPlexis Corporation's (IsoPlexis) single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.

These findings, the result of a collaboration between IsoPlexis and Kite, were presented today at the American Association for Cancer Research's Annual Meeting. 

"IsoPlexis was excited to collaborate with Kite on this groundbreaking research," said IsoPlexis Chief Executive Officer Sean Mackay. "Using our single-cell precision engineering platform, leading oncology and immunotherapy researchers and clinicians were able to collect these data, which demonstrate a potential to optimize therapies and therapeutic interventions for patients, and ultimately drive better patient outcomes in this rapidly growing field."

Researchers used IsoCode, previously referred to as SCBC in the literature, to analyze CAR-T cell therapy products for 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI, or cellular functional profile and strength, of each product. This PSI metric was able to predict complete or partial patient response to the product, with statistical significance.

Adrian Bot, M.D., Kite's Vice President, Translational Medicine, said, "Through this research, we were able to highlight the important role a functionally versatile subpopulation of CAR-T cells may play in the fight against cancer, leading to new ways to characterize and optimize T-cell products. These insights were made possible by using the IsoPlexis technology."

Arnold Levine, PhD, Professor Emeritus of Systems Biology at the Institute for Advanced Study in Princeton and an IsoPlexis Scientific Advisory Board Member, said, "The quality and precision of these data captured by IsoPlexis technology is exceptional and permits for the first time real precision medicine and early intervention in T-cell production." He added, "IsoPlexis technology can help researchers improve the development and targeting of treatments, enabling truly precise medicine and better patient outcomes."

The abstract is available online: http://www.abstractsonline.com/pp8/#!/4292/presentation/1309

A webcast of the presentation will be posted on the AACR website on April 26.

ABOUT ISOPLEXIS:

IsoPlexis is a life sciences company committed to advancing groundbreaking research and therapeutic development in immunology, oncology and other emerging disease areas. The IsoPlexis cellular response analysis platform was developed by scientific leaders at Yale and Caltech. By isolating single immune cells and analyzing their functional omic response, the platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and patient outcomes. Through collaborations with leading pharmaceutical companies and academic labs, the IsoPlexis technology is improving the targeting of breakthrough treatments. The venture capital-funded Yale spinout is headquartered in Branford, Connecticut. For additional information on IsoPlexis, visit http://www.isoplexis.com or email info@isoplexis.com.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/isoplexis-collaboration-offers-breakthrough-insights-into-detecting-and-predicting-patient-response-to-t-cell-therapy-300432888.html


'/>"/>
SOURCE IsoPlexis Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology news :

1. Personalized Medicine - Scientific and Commercial Aspects - 318 Companies Profiled with 575 Collaborations - Research and Markets
2. STMicroelectronics and Valencell Announce Collaboration on Highly Accurate and Powerful Biometric Sensor Platform for Wearables and IoT
3. FIND And Cepheid Announce A Strategic Collaboration To Advance Point-Of-Care TB Diagnosis
4. NXT-ID, Inc. Announces Collaboration with Celebrity Joey Fatone
5. Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health
6. Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc
7. Collaboration drives achievement in protein structure research
8. Calico enters into exclusive collaboration with 2M to develop UTSW technology
9. Research institutions announce collaboration for sharing, standardizing neuroscience data
10. Urban Water Management Workshop stresses more collaboration and innovation
11. ASHG and the Jackson Laboratory launch educational collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2018)... (PRWEB) , ... August 06, 2018 , ... ... of their highly successful business intelligence platform. Inspired by its medical device customers, ... entire user experience on-site. Among the many changes, SmartTRAK 3.0 touts a cleaner ...
(Date:8/2/2018)... ... August 02, 2018 , ... Dickinson Wright PLLC ... has been named Practice Group Chair for the Pharmaceuticals and Biotechnology group of ... Dickinson Wright’s healthcare and life sciences initiatives, and appreciate the opportunity to integrate ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder and ... recipients of the 2018 IAC Awards at the 23rd World Congress on Heart Disease ... named four faculty to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together ...
Breaking Biology News(10 mins):
(Date:8/9/2018)... ... ... Since their establishment in 2012, ambitions have been high at Nicoya Lifesciences. As ... last year, the company is thrilled to announce the release of their new OpenSPR ... private product launch event during the annual Protein Society Symposium in Boston on July ...
(Date:8/9/2018)... ... 2018 , ... Rockland Immunochemicals, Inc. announced today that Dr. ... Antibody Development at Bio-Techne, composed a peer-reviewed article using their combined experience of ... 2018 and will be printed in the September 2018 issue by the journal ...
(Date:8/7/2018)... ... August 06, 2018 , ... ... diagnostics companies, announces the placement of Dr. Paul Harney as President, North America ... America growth strategy and enhancing client satisfaction. He was also named to Prescient’s ...
(Date:8/1/2018)... LOS ANGELES (PRWEB) , ... ... ... an evidence-based healer, today announces research results on the significant impact of ... immune function responses. , The preclinical research assessed biomarkers for systemic ...
Breaking Biology Technology: